UK markets close in 5 hours 30 minutes
  • FTSE 100

    6,865.75
    -118.84 (-1.70%)
     
  • FTSE 250

    16,839.90
    -464.21 (-2.68%)
     
  • AIM

    801.22
    -20.13 (-2.45%)
     
  • GBP/EUR

    1.1186
    +0.0010 (+0.09%)
     
  • GBP/USD

    1.0681
    -0.0050 (-0.47%)
     
  • BTC-GBP

    17,454.75
    -1,509.30 (-7.96%)
     
  • CMC Crypto 200

    426.48
    -32.66 (-7.11%)
     
  • S&P 500

    3,647.29
    -7.75 (-0.21%)
     
  • DOW

    29,134.99
    -125.82 (-0.43%)
     
  • CRUDE OIL

    78.30
    -0.20 (-0.25%)
     
  • GOLD FUTURES

    1,624.50
    -11.70 (-0.72%)
     
  • NIKKEI 225

    26,173.98
    -397.89 (-1.50%)
     
  • HANG SENG

    17,250.88
    -609.43 (-3.41%)
     
  • DAX

    11,914.83
    -224.85 (-1.85%)
     
  • CAC 40

    5,676.08
    -77.74 (-1.35%)
     

Global Biosimilars Market Report 2022: Lower Prices Compared to Branded Products Driving $16.48 Billion Industry

·3-min read
Company Logo
Company Logo

Global Biosimilars Market

Global Biosimilars Market
Global Biosimilars Market

Dublin, Sept. 14, 2022 (GLOBE NEWSWIRE) -- The "Global Biosimilars Market (2022 Edition) - Analysis By Product Type, Application, By Region, By Country: Market Insights and Forecast with Impact of COVID-19 (2023-2028)" report has been added to ResearchAndMarkets.com's offering.

The Global Biosimilars Market was valued at USD 16.48 Billion in the year 2021 with the Europe region leading the regional market share. One of the main factors driving this market is the expiration of patents of major pharmaceutical drugs and thus the opportunity to develop more biosimilar drugs.

Additionally, Biosimilars are priced significantly lower than their reference counterparts, with the increasing burden of health expenditure. Biosimilars provide relief to the healthcare infrastructure of several developing countries and are anticipated to impel market growth in the forecast period.

The Asia Pacific is the fastest growing market in the biosimilars market as countries within the region are providing opportunities to grow and sell medicines. The growing initiatives of the government and increasing investment in healthcare are providing rapid growth.

The FDA reported the shortage of drugs during COVID-19 due to a lack of API and disruptions in the supply chain market. The higher rate of competition in the biosimilar market led to the growth of biologics having long-term supplies. A longer time for approvals was occurring due to a delay in the inspection of the manufacturing facility. The delivery of products is also the major concern impacting the market of biosimilars apart from product manufacturing.

Scope of the Report:

  • The report presents the analysis of Biosimilars Market for the historical period of 2018-2021, estimates of 2022 and the forecast period of 2023-2028.

  • The report analyses the Biosimilars Market by value (USD Billion).

  • The report analyses the Biosimilars Market by Product Type (Monoclonal antibodies, Filgrastim and Pegfilgrastim, Insulin and Others).

  • The report analyses the Biosimilars Market by Application (Oncology, Chronic and Autoimmune Diseases, Blood Disorders, Infectious Diseases, Others).

  • The Global Biosimilars Market has been analysed By Region (Americas, Europe, Asia Pacific, MEA).

  • The Global Biosimilars Market has been analysed By Country (United States, Canada, Germany, United Kingdom, France, Italy, Spain, China, Japan, India).

  • The key insights of the report have been presented through the leading company shares. Also, the attractiveness of the market has been presented by region, by Product Type and by Application.

  • Also, the major opportunities, trends, drivers and challenges of the industry has been analysed in the report.

  • The report tracks competitive developments, strategies, and Major Products & Developments and Mergers & Acquisitions. The companies analysed in the report include Pfizer, Dr.Reddy's Laboratories, Amgen, Novartis AG, Teva Pharmaceuticals Ltd., Samsung Biologics, Eli lilly and company, Stada Arzneimittel, Celltrion, Biocon Limited.

Key Target Audience:

  • Biosimilars Companies

  • Pharmaceutical and Healthcare Companies

  • End Users (Hospitals, Ambulatory Surgical Centres, Research & Laboratories)

  • Research and Development (R&D) Organizations

  • Government Bodies & Regulating Authorities

  • Investment Banks and Equity Firms

Key Topics Covered:

1. Report Scope and Methodology

2. Strategic Recommendations

3. Biosimilars Market: Product Overview

4. 4. Global Biosimilars Market: An Analysis

5. Global Biosimilars Market Segmentation, By Device Type (Value)

6. Global Biosimilars Market Segmentation, By Application (Value)

7. Global Biosimilars Market: Regional Analysis

8. Americas Biosimilars Market: An Analysis (2018-2028)

9. Europe Biosimilars Market: An Analysis (2018-2028)

10. Asia Pacific Biosimilars Market: An Analysis (2018-2028)

11. MEA Biosimilars Market

12. Global Biosimilars Market Dynamics

13. Market Attractiveness and Strategic Analysis

14. Global Biosimilars Market: Competitive Landscape

15. Company Profiles (Business Description, Financial Analysis, Business Strategy)

16. About the Publisher.

For more information about this report visit https://www.researchandmarkets.com/r/nre60t

Attachment

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900